Tristel (TSTL) AI Stock Analysis

• Market Cap: £197.49M
• Dividend Yield: 3.37%
• Average Volume (3M): 111.16K
• Price to Earnings (P/E): 32.1
• Beta (1Y): 0.89
• Revenue Growth: 10.32%
• EPS Growth: 1.25%
• Country: UK
• Employees: 233
• Sector: Healthcare
• Sector Strength: 48
• Industry: Medical - Instruments & Supplies
• EPS (TTM): 0.13
• Shares Outstanding: 47,702,343
• 10 Day Avg. Volume: 58,810
• 30 Day Avg. Volume: 111,155
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 0.00
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: £440.00
• Price Target Upside: 6.28% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

Tristel's overall score is driven by its strong financial performance and promising corporate events. The company is financially stable, with robust revenue growth and efficient cash flow, supported by positive developments such as FDA clearance for new products. However, the technical analysis suggests potential short-term risks due to overbought indicators. The valuation is reasonable, albeit slightly high, balanced by a decent dividend yield. Overall, Tristel is well-positioned for long-term growth, though investors should be mindful of potential short-term volatility.

Tristel Business Overview & Revenue Model

Company Description

Tristel (TSTL) is a UK-based company specializing in infection prevention and contamination control solutions. The company operates primarily within the healthcare sector, providing innovative disinfectant products and technologies that ensure the safety and cleanliness of medical environments. Tristel's core products include proprietary chlorine dioxide-based disinfectants, which are used for the decontamination of medical instruments, surfaces, and environments. The company is committed to enhancing infection control practices across hospitals and other healthcare facilities globally.

How the Company Makes Money

Tristel generates revenue primarily through the sale of its disinfectant products, which are marketed to healthcare institutions worldwide. These products, including their patented chlorine dioxide-based solutions, are sold directly to hospitals and healthcare providers or through a network of distributors. Tristel's revenue streams are bolstered by its strong focus on research and development, leading to continuous innovation and expansion of its product offerings. Additionally, the company benefits from strategic partnerships and collaborations that enhance its market presence and distribution capabilities. Regulatory approvals and certifications in various countries also play a crucial role in facilitating the company's international sales and growth.

Tristel Financial Statement Overview

Summary

Income Statement

Balance Sheet

Cash Flow

Breakdown
Jun 2024	Jun 2023	Jun 2022	Jun 2021	Jun 2020
Income Statement		Total Revenue
41.93M	36.01M	31.12M	31.00M	31.68M
	Gross Profit
30.87M	29.18M	24.66M	24.74M	25.25M
	EBIT
7.05M	5.28M	4.20M	4.76M	6.80M
	EBITDA
10.01M	7.84M	4.46M	6.70M	9.30M
	Net Income Common Stockholders
6.49M	4.46M	987.00K	3.66M	5.10M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
11.79M	9.54M	8.88M	8.09M	6.21M
	Total Assets
44.11M	41.37M	38.74M	39.93M	40.93M
	Total Debt
5.86M	5.18M	5.81M	5.91M	6.00M
	Net Debt
-275.00K	-1.93M	-3.07M	-2.19M	-210.00K
	Total Liabilities
11.70M	10.68M	9.75M	9.85M	12.47M
	Stockholders Equity
32.41M	30.68M	28.98M	30.08M	28.46M
Cash Flow		Free Cash Flow
10.06M	6.07M	4.35M	4.71M	4.61M
	Operating Cash Flow
11.20M	8.49M	5.55M	6.48M	6.99M
	Investing Cash Flow
-5.40M	-4.84M	-1.20M	-1.77M	-2.97M
	Financing Cash Flow
-6.57M	-5.44M	-3.62M	-2.83M	-2.02M

Tristel Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 414.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:TSTL, the sentiment is Positive. The current price of 414 is above the 20-day moving average (MA) of 359.65, above the 50-day MA of 332.37, and above the 200-day MA of 383.62, indicating a bullish trend. The MACD of 22.10 indicates Negative momentum. The RSI at 79.91 is Negative, neither overbought nor oversold. The STOCH value of 88.18 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GB:TSTL.

Tristel Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TSTL	76 Outperform	£197.49M	32.07	19.61%	3.37%	10.32%	1.25%
CTEC	76 Outperform	£5.35B	35.99	11.12%	1.93%	3.94%	41.63%
ANCR	75 Outperform	£173.84M	4.78	33.70%	1.98%	-0.17%	2591.96%
NIOX	74 Outperform	£271.56M	77.27	4.55%	1.47%	13.59%	-66.27%
EKF	71 Outperform	£91.69M	14.78	8.95%	5.88%	-4.59%	165.38%
AMS	66 Neutral	£420.20M	59.15	2.95%	1.24%	40.66%	-55.36%
Sector *	52 Neutral	$5.22B	3.55	-44.39%	2.82%	15.40%	-0.09%

Tristel Corporate Events

Tristel Secures FDA Clearance for Ophthalmic Disinfectant in US Market

Tristel plc has received FDA clearance for its Tristel OPH, a high-level disinfectant foam for ophthalmic medical devices, marking a significant advancement in the US market. This clearance allows Tristel to address the inefficiencies and safety concerns of existing disinfection methods, offering a faster and safer alternative that is compatible with widely used devices. The company has already established local manufacturing in the US and is poised to support early adopters, potentially transforming ophthalmic disinfection practices in North America.

Spark’s Take on GB:TSTL Stock

According to Spark, TipRanks’ AI Analyst, GB:TSTL is a Outperform.

Tristel scores well overall due to its strong financial health and positive corporate events, which are primary drivers of the company’s promising outlook. However, caution is advised due to mixed technical indicators suggesting potential short-term volatility. The balanced valuation adds support, making Tristel a strong candidate for long-term investment.

To see Spark’s full report on GB:TSTL stock, click here.

Tristel Submits Additional Data to FDA for Ophthalmic Disinfectant Approval

Tristel plc has submitted additional information to the FDA for its Tristel OPH, a high-level disinfectant foam for ophthalmic devices, with an expected decision by June 2025. The approval could significantly impact ophthalmic disinfection practices in North America, addressing inefficiencies and improving safety standards. The company aims to leverage this opportunity to enhance its market presence and reach key decision-makers at the upcoming APIC conference.

Spark’s Take on GB:TSTL Stock

According to Spark, TipRanks’ AI Analyst, GB:TSTL is a Outperform.

Tristel’s strong financial health and positive corporate events are the primary drivers of its score, indicating a promising outlook for growth and stability. However, bearish technical indicators suggest potential short-term challenges. The balanced valuation adds support, making Tristel a strong candidate for long-term investment, especially considering the company’s strategic initiatives and insider confidence.

To see Spark’s full report on GB:TSTL stock, click here.

Tristel’s Disinfection Foam Gains Recognition and Boosts North American Sales

Tristel plc announced the publication of a poster by the Mayo Clinic at the AORN Global Surgical Conference & Expo, detailing the successful trial of Tristel ULT™, a high-level disinfection foam for ultrasound probes. The trial, which involved 11 Mayo Clinic staff members and 189 ultrasound probes, reported no surgical site infections and highlighted the foam’s effectiveness, efficiency, and cost-effectiveness. This development follows recognition by the AAMI and ANSI of chlorine dioxide foam as a novel disinfection method and adds to the growing number of US case studies supporting Tristel ULT™. Tristel’s sales in North America are experiencing strong growth, with over 200,000 disinfection procedures conducted this financial year, reflecting increasing adoption and customer engagement.

Spark’s Take on GB:TSTL Stock

According to Spark, TipRanks’ AI Analyst, GB:TSTL is a Neutral.

Tristel’s overall score reflects its strong financial health and positive corporate events, tempered by bearish technical indicators. The balanced valuation provides an additional support to the stock’s prospects. Strategic growth initiatives and insider confidence bolster the company’s future outlook.

To see Spark’s full report on GB:TSTL stock, click here.

Tristel CFO Increases Stake in Company

Tristel plc announced that its Chief Financial Officer, Liz Dixon, purchased 5,000 ordinary shares of the company at a price of 291.99 pence per share, increasing her beneficial interest to 155,000 shares, which represents 0.32% of the company’s total issued share capital. This transaction reflects confidence in the company’s operations and could positively impact stakeholder perception, reinforcing Tristel’s strong positioning in the infection prevention industry.

Tristel CEO Increases Stake, Signaling Confidence in Company’s Future

Tristel plc announced that its CEO, Matthew Sassone, has purchased 3,500 ordinary shares of the company at 310 pence per share, increasing his beneficial interest to 0.007% of the total issued share capital. This move may signal confidence in the company’s future prospects and could positively influence stakeholder perceptions, reinforcing the company’s market position in the infection prevention industry.

Tristel PLC Reports Strong Interim Results with Strategic Growth Initiatives

Tristel PLC reported strong interim results for the six months ending December 2024, with an 8% revenue increase to £22.6 million and a 19% rise in adjusted profit before tax to £4.9 million. The company remains debt-free and cash-generative, maintaining a progressive dividend policy. Tristel’s expansion efforts are centered on geographic growth, particularly in the USA, where they anticipate significant opportunities. Key operational highlights include the successful transition of the CEO and a strategic FDA filing for a new disinfectant product, indicating promising growth prospects and industry positioning.